Perceptions of medication safety among patients with inflammatory bowel disease.

Hdl Handle:
http://hdl.handle.net/10147/126546
Title:
Perceptions of medication safety among patients with inflammatory bowel disease.
Authors:
Cullen, Garret; Donnellan, Fergal; Long, Syapiq; Forry, Mary; Murray, Frank E
Affiliation:
Department of Gastroenterology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland. garret.cullen@ucd.ie
Citation:
Perceptions of medication safety among patients with inflammatory bowel disease. 2010, 45 (9):1076-83 Scand. J. Gastroenterol.
Journal:
Scandinavian journal of gastroenterology
Issue Date:
Sep-2010
URI:
http://hdl.handle.net/10147/126546
DOI:
10.3109/00365521.2010.490595
PubMed ID:
20459367
Abstract:
The aim of this study was to assess attitudes towards and knowledge of medication safety in inflammatory bowel disease (IBD). IBD patients frequently require long-term treatment with potentially toxic medications. Techniques are employed to improve patient awareness of medication safety, but there are sparse data on their effectiveness.; Questionnaires relating to the safety and efficacy of commonly used IBD treatments (aminosalicylates, corticosteroids, immunomodulators, biologics) were completed by IBD patients attending the gastroenterology clinics at a teaching hospital.; One hundred patients (51 male) with a median (interquartile range) age of 37 (29-49) years were included: 56 Crohn's disease, 44 ulcerative colitis. Aminosalicylates (median 0.8 (IQR 0.1-1.9)) were ranked as the safest medication; corticosteroids (4.6 (1.1-8.2)), immunomodulators (4.2 (1.1-8.4) and biologics (4.4 (1.1-6.8)) were ranked equally. 36%, 53% and 79% reported no knowledge regarding safety of corticosteroids, immunomodulators and biologics, respectively. Most patients wish to be informed of all medication side-effects, no matter how rare, and ranked their gastroenterologist as their primary information source.; IBD patients want to be informed of all potential adverse events and identify their gastroenterologist as their principal information source. The majority have no knowledge regarding or underestimate the toxicity of common IBD medications. This places a responsibility on gastroenterologists to manage and meet patients' expectations in the area of medication safety.
Item Type:
Article
Language:
en
MeSH:
Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Female; Health Knowledge, Attitudes, Practice; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Perception; Questionnaires; Treatment Outcome
ISSN:
1502-7708

Full metadata record

DC FieldValue Language
dc.contributor.authorCullen, Garreten
dc.contributor.authorDonnellan, Fergalen
dc.contributor.authorLong, Syapiqen
dc.contributor.authorForry, Maryen
dc.contributor.authorMurray, Frank Een
dc.date.accessioned2011-03-31T12:48:10Z-
dc.date.available2011-03-31T12:48:10Z-
dc.date.issued2010-09-
dc.identifier.citationPerceptions of medication safety among patients with inflammatory bowel disease. 2010, 45 (9):1076-83 Scand. J. Gastroenterol.en
dc.identifier.issn1502-7708-
dc.identifier.pmid20459367-
dc.identifier.doi10.3109/00365521.2010.490595-
dc.identifier.urihttp://hdl.handle.net/10147/126546-
dc.description.abstractThe aim of this study was to assess attitudes towards and knowledge of medication safety in inflammatory bowel disease (IBD). IBD patients frequently require long-term treatment with potentially toxic medications. Techniques are employed to improve patient awareness of medication safety, but there are sparse data on their effectiveness.-
dc.description.abstractQuestionnaires relating to the safety and efficacy of commonly used IBD treatments (aminosalicylates, corticosteroids, immunomodulators, biologics) were completed by IBD patients attending the gastroenterology clinics at a teaching hospital.-
dc.description.abstractOne hundred patients (51 male) with a median (interquartile range) age of 37 (29-49) years were included: 56 Crohn's disease, 44 ulcerative colitis. Aminosalicylates (median 0.8 (IQR 0.1-1.9)) were ranked as the safest medication; corticosteroids (4.6 (1.1-8.2)), immunomodulators (4.2 (1.1-8.4) and biologics (4.4 (1.1-6.8)) were ranked equally. 36%, 53% and 79% reported no knowledge regarding safety of corticosteroids, immunomodulators and biologics, respectively. Most patients wish to be informed of all medication side-effects, no matter how rare, and ranked their gastroenterologist as their primary information source.-
dc.description.abstractIBD patients want to be informed of all potential adverse events and identify their gastroenterologist as their principal information source. The majority have no knowledge regarding or underestimate the toxicity of common IBD medications. This places a responsibility on gastroenterologists to manage and meet patients' expectations in the area of medication safety.-
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAnti-Inflammatory Agents-
dc.subject.meshColitis, Ulcerative-
dc.subject.meshCrohn Disease-
dc.subject.meshFemale-
dc.subject.meshHealth Knowledge, Attitudes, Practice-
dc.subject.meshHumans-
dc.subject.meshInflammatory Bowel Diseases-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPerception-
dc.subject.meshQuestionnaires-
dc.subject.meshTreatment Outcome-
dc.titlePerceptions of medication safety among patients with inflammatory bowel disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Gastroenterology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland. garret.cullen@ucd.ieen
dc.identifier.journalScandinavian journal of gastroenterologyen
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.